Skip to main content
. Author manuscript; available in PMC: 2018 Feb 20.
Published in final edited form as: Shock. 2009 Dec;32(6):614–620. doi: 10.1097/SHK.0b013e3181a4fd8f

Fig. 5. Rimonabant (RMN) attenuates the rise in plasma TNF-α concentrations caused by LPS administration.

Fig. 5

Groups of five rats were treated with intracerebroventricular rimonabant (250 ng) or vehicle, followed 2 min later by LPS (1 mg/kg, i.v.). Blood was collected at the indicated time interval after LPS (1 mg/kg, i.v.) administration, and plasma TNF-α concentrations were analyzed by enzyme immunoassay. Data were analyzed by using two-way repeated-measure ANOVA, followed by Tukey test. *P < 0.05, significantly different from the vehicle + LPS group. ND indicates nondetectable.